Curbstone Financial Management Corp Trims Stake in Johnson & Johnson $JNJ

Curbstone Financial Management Corp reduced its position in Johnson & Johnson (NYSE:JNJ) by 4.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,712 shares of the company’s stock after selling 1,209 shares during the quarter. Johnson & Johnson accounts for approximately 0.8% of Curbstone Financial Management Corp’s holdings, making the stock its 28th biggest holding. Curbstone Financial Management Corp’s holdings in Johnson & Johnson were worth $3,928,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Foster & Motley Inc. raised its position in Johnson & Johnson by 2.1% in the 2nd quarter. Foster & Motley Inc. now owns 49,385 shares of the company’s stock worth $7,544,000 after purchasing an additional 998 shares during the period. Chevy Chase Trust Holdings LLC raised its position in Johnson & Johnson by 0.6% in the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 1,401,388 shares of the company’s stock worth $214,062,000 after purchasing an additional 9,043 shares during the period. Arista Wealth Management LLC bought a new position in Johnson & Johnson in the 2nd quarter worth about $1,489,000. Sage Private Wealth Group LLC grew its stake in Johnson & Johnson by 13.0% in the 2nd quarter. Sage Private Wealth Group LLC now owns 3,304 shares of the company’s stock worth $505,000 after acquiring an additional 381 shares in the last quarter. Finally, Stratos Investment Management LLC grew its stake in Johnson & Johnson by 5.8% in the 2nd quarter. Stratos Investment Management LLC now owns 19,948 shares of the company’s stock worth $3,047,000 after acquiring an additional 1,094 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

NYSE JNJ opened at $193.27 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm’s 50 day moving average price is $180.49 and its 200-day moving average price is $164.90. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.40. The company has a market cap of $465.45 billion, a PE ratio of 18.65, a P/E/G ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on JNJ. The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Bank of America upped their target price on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. Cowen restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Barclays upped their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $209.00 price objective on shares of Johnson & Johnson in a research note on Friday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $199.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.